Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Leukotriene antagonists--do they have a value?].

C Stey1

  • 1Medizinische Poliklinik Universitätsspital Zürich. claudia.stey@dim.usz.ch

Praxis
|May 18, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exertional dyspnea as initial manifestation of Takayasu's arteritis--a case report and literature review.

BMC pulmonary medicine·2002
Same author

[Description of Internet-based models for continuing medical education. First results and experiences with asthma patients].

Zeitschrift fur arztliche Fortbildung und Qualitatssicherung·2001
Same author

[Lung infiltrations in Hodgkin lymphoma].

Praxis·2001
Same author

The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review.

The European respiratory journal·2000
Same author

[Practical considerations in management of adult asthmatic patients].

Praxis·2000
Same author

[Sarcoidosis: acute versus chronic--2 case reports].

Praxis·2000

Leukotriene receptor antagonists (LTRA) improve mild-to-moderate asthma but are less effective and more costly than inhaled steroids. LTRA are best for patients with aspirin-sensitive asthma or those needing reduced corticosteroid doses.

Area of Science:

  • Pulmonology
  • Pharmacology

Background:

  • Asthma management guidelines prioritize long-term disease control.
  • Leukotriene receptor antagonists (LTRA) represent a novel maintenance therapy for chronic asthma.
  • Zafirlukast (Accolate) and montelukast (Singulair) are available LTRA in Switzerland.

Purpose of the Study:

  • To evaluate the efficacy and cost-effectiveness of LTRA in asthma treatment.
  • To compare LTRA with placebo and inhaled corticosteroids (ICS).
  • To identify patient subgroups that benefit most from LTRA therapy.

Main Methods:

  • Clinical trials comparing LTRA to placebo for mild-to-moderate asthma.
  • Comparative studies assessing LTRA efficacy against low-dose inhaled steroids.
  • Analysis of cost-effectiveness data for LTRA and ICS.

Related Experiment Videos

  • Subgroup analysis focusing on patients with aspirin-sensitive asthma.

    • Main Results:

    • LTRA demonstrated significant improvements in lung function, symptoms, and reduced exacerbations compared to placebo.
    • LTRA were found to be less effective and more expensive than low-dose inhaled steroids.
    • LTRA facilitated a reduction in inhaled corticosteroid doses for patients on moderate to high doses.
    • Patients with aspirin-sensitive asthma showed the best response to LTRA.

    Conclusions:

    • Inhaled steroids remain the preferred, most cost-effective first-line therapy for chronic asthma.
    • LTRA are a valuable option for specific patient groups, including those with aspirin sensitivity or requiring ICS dose reduction.
    • The use of LTRA should be considered within the context of efficacy and cost compared to inhaled steroids.